{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-024112","form_type":"8-K","ticker":"AVBP","cik":"0001868279","company_name":"ArriVent BioPharma, Inc.","filed_at":"2026-03-05T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.615824+00:00","generated_at":"2026-05-15T19:54:14.403300+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"ArriVent reports FY2025 net loss of $166.3M; cash of $312.8M funds into 3Q 2027","bullets":["Cash and investments of $312.8M as of Dec 31, 2025; expected to fund operations into 3Q 2027.","Net loss $166.3M in FY2025 vs $80.5M in FY2024; R&D expenses $153.4M (incl. one-time payment to Lepu).","Topline pivotal Phase 3 data for firmonertinib in first-line EGFR exon20ins NSCLC expected mid-2026.","Phase 3 ALPACCA study for firmonertinib in EGFR PACC mutant NSCLC dosed first patient in Dec 2025.","ADC lead ARR-217 in Phase 1 dose escalation; IND clearance received; first patient dosed March 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-024112","json":"https://secwatch.observer/filing/0001104659-26-024112.json","markdown":"https://secwatch.observer/filing/0001104659-26-024112.md","text":"https://secwatch.observer/filing/0001104659-26-024112.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1868279/000110465926024112/0001104659-26-024112-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1868279/000110465926024112/avbp-20260305x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T19:54:14.403300+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"619e61073afa6273cc08156e000bfc7e28a375a2","claim":"ArriVent BioPharma, Inc. reported the year ended December 31, 2025 results: net income Net loss was $166.3 million.","evidence_excerpt":"ArriVent BioPharma, Inc. (the “Company”) issued a press release announcing its financial results for the fourth quarter and full year ended December 31, 2025.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1868279/000110465926024112/0001104659-26-024112-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the year ended December 31, 2025"},{"label":"Net income","value":"Net loss was $166.3 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}